KINIKSA PHARMACEUTICALS, LTD. Kiniksa Pharmaceuticals, Ltd. Share Price
Equities
KNSA
BMG5269C1010
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.88 USD | +1.53% |
|
+5.74% | +1.94% |
| 23/04 | Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises | MT |
| 23/04 | Transcript : Kiniksa Pharmaceuticals, Ltd., Q1 2024 Earnings Call, Apr 23, 2024 |
| Sales 2024 * | 387M 32.25B | Sales 2025 * | 525M 43.81B | Capitalization | 1.27B 106B |
|---|---|---|---|---|---|
| Net income 2024 * | -10M -834M | Net income 2025 * | 38M 3.17B | EV / Sales 2024 * | 2.65 x |
| Net cash position 2024 * | 242M 20.2B | Net cash position 2025 * | 386M 32.19B | EV / Sales 2025 * | 1.68 x |
| P/E ratio 2024 * |
-122
x | P/E ratio 2025 * |
32.7
x | Employees | 297 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.58% |
More Fundamentals
* Assessed data
More news
Latest transcript on Kiniksa Pharmaceuticals, Ltd.
More recommendations
More press releases
| 1 day | +1.53% | ||
| 1 week | +5.74% | ||
| Current month | -9.38% | ||
| 1 month | -10.47% | ||
| 3 months | -1.87% | ||
| 6 months | +18.02% | ||
| Current year | +1.94% |
1 week
16.87
18.61
1 month
16.5620.13
Current year
16.5622.09
1 year
10.6522.09
3 years
7.3622.09
5 years
5.0128.67
10 years
5.0132.88
| Managers | Title | Age | Since |
|---|---|---|---|
Eben Tessari
FOU | Founder | 42 | 01/15/01 |
Sanj Patel
CEO | Chief Executive Officer | 54 | 01/15/01 |
Mark Ragosa
DFI | Director of Finance/CFO | 50 | 01/18/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Felix Baker
BRD | Director/Board Member | 55 | 01/15/01 |
Barry D. Quart
BRD | Director/Board Member | 67 | 01/15/01 |
Thomas Malley
BRD | Director/Board Member | 55 | 01/16/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 2 M€ | -.--% | ||
| 0.05% | 0 M€ | 0.00% | - | |
| 0.04% | 0 M€ | 0.00% | - | |
| 0.03% | 7 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 17.88 | +1.53% | 331,616 |
| 25/24/25 | 17.61 | -1.40% | 477,277 |
| 24/24/24 | 17.86 | +1.02% | 443,785 |
| 23/24/23 | 17.68 | +3.42% | 611,899 |
| 22/24/22 | 17.1 | +1.09% | 361,220 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Companyâs ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Companyâs Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Calendar
31/07/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
17.88
USD
Average target price
29.2
USD
Spread / Average Target
+63.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.94% | 1.27B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- KNSA Stock
